Clinical Trials Browser

Phase 2/3 × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all

NCT05625633 2024-04-05

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Phase 2/3 Recruiting

Warts, Papillomavirus Infections